Get the Stockscreener App
490.28
19.01%
-115.11
Regeneron Pharmaceuticals Inc stock is traded at $490.28, with a volume of 6.31M.
It is down -19.01% in the last 24 hours and down -13.82% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$605.39
Open:
$517.655
24h Volume:
6.31M
Relative Volume:
5.40
Market Cap:
$52.04B
Revenue:
$14.09B
Net Income/Loss:
$4.50B
P/E Ratio:
12.48
EPS:
39.28
Net Cash Flow:
$2.96B
1W Performance:
-16.67%
1M Performance:
-13.82%
6M Performance:
-34.65%
1Y Performance:
-49.45%
1-Day Range:
$485.00
$519.78
1-Week Range:
$485.00
$608.17
52-Week Range:
$485.00
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by GuoLine Advisory Pte Ltd - MarketBeat
Regeneron Pharmaceuticals Inc Says Libtayo Shows 68% Reduction In Risk Of Disease Recurrence Or Death - marketscreener.com
Breakthrough Phase 3 Results: Libtayo Cuts Skin Cancer Recurrence Risk by 68%, Could Transform Treatment - Stock Titan
‘Time to Choose Sides on Salesforce (NYSE:CRM),’ Analysts are Split on the Stock - The Globe and Mail
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Summit Global Investments - MarketBeat
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed On Friday - Insider Monkey
Mackenzie Financial Corp Sells 960 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rep. Byron Donalds Sells Off Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron shares slide on mixed trial data for smoker's lung drug - MSN
S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet - Investopedia
Regeneron (REGN) Price Target Reduced by Leerink Following Trial Setback | REGN Stock News - GuruFocus
Regeneron stock sinks over trial data for smoker's lungs drug - Yahoo Finance
Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily
Forecasting The Future: 21 Analyst Projections For Regeneron Pharmaceuticals - Nasdaq
Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure - MarketWatch
Boston Common Asset Management LLC Acquires 5,525 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (REGN) Faces Rating Downgrade by Wells Fargo | REGN Stock News - GuruFocus
Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive Investors
Itepekimab Failure A Setback For Sanofi And Regeneron (SNY) - Seeking Alpha
Why Regeneron (REGN) Shares Are Falling Today - MSN
RBC Capital cuts Regeneron stock rating, slashes target to $662 - Investing.com
Regeneron (REGN) Faces Downgrade as New Drug Prospects Dim | REG - GuruFocus
Jefferies Lowers Regeneron Pharmaceuticals' Price Target to $804 From $914 - marketscreener.com
RBC Capital Downgrades Regeneron Pharmaceuticals to Sector Perform From Outperform, Price Target is $662 - marketscreener.com
Regeneron (REGN) Downgraded by RBC Capital with Adjusted Price T - GuruFocus
RBC Reaffirms Outperform on Regeneron (REGN) Ahead of Key COPD Drug Results - MSN
Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More - MSN
Unity upgrade, UiPath earnings, Regeneron drug trial results - Yahoo Finance
Regeneron stock crashes on COPD data: here’s why I’m buying REGN today - TradingView
Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies - sharewise
Regeneron (REGN) Faces Setback with Phase 3 Trial Failure - GuruFocus
Guggenheim maintains Regeneron stock buy rating, $810 target - Investing.com
Regeneron stock holds after mixed Phase 3 study results By Investing.com - Investing.com India
Regeneron stock downgraded at Wells Fargo (REGN:NASDAQ) - Seeking Alpha
Split ends itepekimab in COPD? Regeneron phase III setup hairy - BioWorld MedTech
Citigroup Cuts Price Target on Regeneron Pharmaceuticals to $650 From $700 - marketscreener.com
Centre Asset Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sanofi, Regeneron Shares Tumble as Dupixent Follow-Up Fails Phase III COPD Test - BioSpace
Stock Movers: Ulta Beauty, Cooper Companies, Regeneron Pharmaceuticals - Bloomberg.com
COPD Drug Developed by Regeneron, Sanofi Fails Key Test - Investopedia
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - AOL.com
Mixed COPD results for Regeneron, Sanofi drug cloud approval chances - BioPharma Dive
Baird maintains Neutral on Regeneron, price target at $587 By Investing.com - Investing.com India
BMO maintains Regeneron stock Outperform rating, $800 target By Investing.com - Investing.com India
Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. - Barron's
Regeneron’s Stock (REGN) Makes New Low: Trial Data Disappoints, Analyst Trims PT - AskTraders.com
Regeneron stock touches 52-week low at $518.68 amid market shifts - Investing.com Australia
Regeneron stock holds as Oppenheimer keeps $900 target - Investing.com
Regeneron stock holds as Oppenheimer keeps $900 target By Investing.com - Investing.com UK
Regeneron (REGN) Downgraded by Wells Fargo After Disappointing D - GuruFocus
Regeneron (REGN) Downgraded by Wells Fargo with Adjusted Price T - GuruFocus
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.79%
3.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):